Mission Therapeutics Ltd Appoints David Luther As Chief Financial Officer

Expands management team with accomplished senior executive

CAMBRIDGE, UK – 1st October 2015 – MISSION Therapeutics, a drug discovery and development company focused on selectively targeting deubiquitylating (DUB) enzymes to treat cancer and other diseases, announced the appointment of David Luther as Chief Financial Officer, to take effect from 1st October 2015.

Mr Luther brings more than 25 years' financial and operational experience, across the healthcare, FMCG and pharmaceutical industries. He joins MISSION from Spotless Group, a private equity backed FMCG business, having successfully supported them in a trade exit to Henkel. He served as VP Finance for commercial and supply chain operations in the UK, Ireland and Italy.

Prior to the Spotless Group, Mr Luther was Finance Director for the Italian operations of Aptuit, a global healthcare contract services organisation, and prior to this spent 15 years at GlaxoSmithKline (GSK). At GSK, Mr Luther held a number of senior roles, including Director, Corporate Development, responsible for M&A transactions, Finance Director Neurosciences, helping to create GSK's innovative drug discovery concept, commercial Finance Director positions in Hungary and Poland, and initially as an Operations Consultant, performing consulting and compliance reviews across the organisation.

Mr Luther trained and qualified as an ACA with KPMG and has a BSc in Biochemistry from the University of Surrey. He has lived and worked in the UK, USA, Poland, Hungary, Italy and South Africa.

Commenting on the appointment, Dr Anker Lundemose, Chief Executive Officer of MISSION Therapeutics, said: "David's financial acumen, extensive experience and exemplary track record in both large pharma and private equity-backed companies will be invaluable to MISSION. This welcome appointment comes at a pivotal moment in our corporate development and complements the senior management team as our assets grow with the success of our discovery programmes."

David Luther, newly appointed Chief Financial Officer of MISSION Therapeutics, added: "I am very enthusiastic about joining the highly experienced MISSION management team and look forward to working with them and the Company's investors to create and deliver value from the diverse therapeutic opportunities generated by the Company's discovery platform."

CONTACT:

MISSION Therapeutics Ltd
Anker Lundemose MD PhD
Chief Executive Officer
Tel +44 1223 497454

Hume Brophy
Mary Clark, Eva Haas, Hollie Vile
Email: [email protected]
Tel: +44 203 440 5654

NOTES TO EDITORS:

About MISSION Therapeutics

MISSION Therapeutics was founded in 2011 to commercialise expert research into the ubiquitin pathway for the treatment of cancers and other diseases of unmet need. It has built a World-leading platform for the discovery and development of first-in-class, small molecule drugs that selectively target deubiquitylating enzymes (DUBs) – an emerging, and hitherto intractable, drug class that is attracting significant commercial interest as the potential 'Next Kinase Area'.

MISSION's leadership team has a wealth of international, commercial and scientific experience and the company has strong links with key academic and research centers including Cancer Research UK laboratories and the Jackson Laboratories at the Gurdon Institute, University of Cambridge.

The Company has received £27 million in venture capital from a blue chip syndicate comprising institutional (Sofinnova Partners, Imperial Innovations) and corporate (SR One, Roche Venture Fund and Pfizer) investors, and was awarded a £1.9 million grant from Innovate UK in September 2015. MISSION is based at the Babraham Research Campus, south of Cambridge.

Suggested Articles

In this week's EuroBiotech Report, Sanofi cuts staff in R&D rejig, AstraZeneca bets on Korea and uniQure weighs buyout bids.

In our EuroBiotech roundup this week, BioNTech and Genmab start cancer trial, Oncopeptides posts cancer data and F-star hires CFO.

Chief Operating Officer Dan Paterson will lead the company while it looks for a permanent successor with commercial chops.